Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2003-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months prior to screening. Patients whose diabetes management consists of diet and exercise will also be eligible for this study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Exenatide

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes

• Treated with diet and exercise alone or with metformin for at least 3 months prior to screening

• BMI 27-45 kg/m^2

• HbA1c between 7.0 % and 8.0 %

Exclusion Criteria:

• Treated with other oral anti-diabetic agents other than metformin within 3 months of screening

• Patients previously treated with AC2993

• Patients presently treated with insulin